New combo therapy offers hope for deadly lung disease flare-ups

NCT ID NCT03286556

First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 8 times

Summary

This study tested a treatment combining plasma exchange, rituximab, and intravenous immunoglobulin in 82 people with idiopathic pulmonary fibrosis experiencing sudden, severe worsening. The goal was to see if this approach could improve survival by targeting harmful antibodies. The therapy aims to control the disease during these life-threatening episodes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS, ACUTE FATAL FORM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Baylor University Medical Center

    Houston, Texas, 77030, United States

  • Dan Dilling

    Chicago, Illinois, 60611, United States

  • Temple University Hospital

    Philadelphia, Pennsylvania, 19140, United States

  • Thomas Jefferson University Medical Center

    Philadelphia, Pennsylvania, 19107, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Utah Medical Center

    Salt Lake City, Utah, 84112, United States

Conditions

Explore the condition pages connected to this study.